Q3 EPS Estimate for Agilent Technologies Lowered by Analyst

Key Points

• Leerink Partners has lowered its Q3 2026 EPS estimate for Agilent Technologies from $1.53 to $1.52, while also forecasting Q4 2026 earnings at $1.65 EPS.
• Agilent Technologies reported Q3 earnings of $1.37 EPS, meeting analysts' expectations, with revenue of $1.74 billion surpassing the anticipated $1.67 billion.
• Stock ratings for Agilent Technologies show a mixed sentiment, with some analysts issuing a "buy" rating and others maintaining a "neutral" stance, resulting in an average rating of "Moderate Buy."

Agilent Technologies, Inc. (NYSE:A - Free Report) - Stock analysts at Leerink Partnrs dropped their Q3 2026 earnings per share estimates for Agilent Technologies in a research note issued on Wednesday, August 27th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $1.52 for the quarter, down from their previous estimate of $1.53. The consensus estimate for Agilent Technologies' current full-year earnings is $5.58 per share. Leerink Partnrs also issued estimates for Agilent Technologies' Q4 2026 earnings at $1.65 EPS, FY2026 earnings at $5.91 EPS and FY2027 earnings at $6.48 EPS.

A number of other research analysts have also commented on A. Robert W. Baird upped their price objective on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a research report on Thursday, August 28th. Wells Fargo & Company upped their price objective on shares of Agilent Technologies from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. Barclays reiterated an "equal weight" rating and set a $125.00 price target on shares of Agilent Technologies in a research note on Friday, August 29th. UBS Group decreased their price target on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a research note on Thursday, May 29th. Finally, Evercore ISI decreased their target price on shares of Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a research report on Thursday, August 28th. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $139.25.

Agilent Technologies Stock Performance

Shares of A traded up $2.09 during trading hours on Monday, reaching $127.31. 1,044,914 shares of the company traded hands, compared to its average volume of 1,952,557. The stock's fifty day moving average is $118.85 and its 200 day moving average is $116.42. The stock has a market cap of $36.16 billion, a P/E ratio of 29.90, a price-to-earnings-growth ratio of 3.91 and a beta of 1.24. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.60 and a current ratio of 2.25. Agilent Technologies has a 1-year low of $96.43 and a 1-year high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm's revenue was up 10.1% compared to the same quarter last year. During the same period last year, the business posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS.

Insider Buying and Selling at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the sale, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. This trade represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.26% of the company's stock.

Institutional Investors Weigh In On Agilent Technologies

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Agilent Technologies by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 33,997,845 shares of the medical research company's stock worth $4,012,086,000 after purchasing an additional 589,219 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in Agilent Technologies by 10.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company's stock worth $1,560,964,000 after buying an additional 1,273,994 shares in the last quarter. Geode Capital Management LLC lifted its position in Agilent Technologies by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 7,319,530 shares of the medical research company's stock worth $860,137,000 after buying an additional 115,183 shares in the last quarter. Generation Investment Management LLP lifted its position in Agilent Technologies by 15.9% during the 2nd quarter. Generation Investment Management LLP now owns 5,775,860 shares of the medical research company's stock worth $681,609,000 after buying an additional 792,304 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its position in Agilent Technologies by 2.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company's stock worth $624,888,000 after buying an additional 128,131 shares in the last quarter. Institutional investors and hedge funds own 87.41% of the company's stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.